Up to 70% of women who quit smoking relapse after birth, usually within 3 months postpartum. The wide adoption of mobile technologies, especially smartphones, in recent years in low-and middle-income countries (LMICs) offers the possibility of low-cost, novel, and innovative mobile phone-based interventions for smoking relapse prevention. This study presents the protocol of the RESPREMO clinical trial for postnatal smoking relapse prevention for enrolled women, who recently gave birth and quit tobacco smoking before or during pregnancy, and their life partners. This work relies on data collected in two of the largest government-owned obstetrics and gynecology clinics in Cluj-Napoca, Romania. Seventy-five couples were randomized into one of three groups: a) 24 couples were allocated to the first intervention group and asked to install and use the xSmoker app; b) 26 couples were randomized to the second intervention group, who, in addition to the use of the xSmoker app, received text messages with content focused on motivation, problem solving, and dyadic efficacy; and c) 25 couples were randomized into a control group. Several measures of engagement with the xSmoker app were assessed, including duration of app use, the frequency of utilizing the tool to calculate savings from quitting, number of app-delivered challenges accepted by users, and number of app-delivered cessation and abstinence tips. If effective, RESPREMO is expected to have a sustainable impact on the prevention of postnatal relapse tobacco smoking with positive effects for both the mother and the newborn. The implications are beyond tobacco control, and relevant to the design and implementation of other mHealth behavioral interventions focused on the pregnancy and reproductive years in general.

No abstract

Alcohol abuse is one of the most common causes of substance dependence, representing an area ofinterest in continuous development. In terms of treatment, Gabapentin (GBP) has shown in published studies that it is an important therapeutic agent, especially in the case of alcohol withdrawal syndrome. The main objective of this article is to carry out a detailed evaluation of studies on the effectiveness of Gabapentin in the treatment of numerous mental disorders and also substance use disorders. Although it belongs to the category of anticonvulsants, it has been shown that Gabapentin has many therapeutic properties due to its mechanism of action involving the Gabaergic system. Thus, a new therapeutic vision in the treatment of abstinence and withdrawal syndrome is outlined.